ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference Thursday, March 2, 2023 CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for multiple CNS and other inflammatory diseases
